Results from an interim analysis of the Guinea Phase III efficacy vaccine trial show that VSV-EBOV (Merck, Sharp & Dohme) is highly effective against Ebola. The independent body of international experts - the Data and Safety Monitoring Board – that conducted the review, advised that the trial should continue. Preliminary results from analyses of these interim data are published today in the British journal The Lancet.
"This is an extremely promising development," said Dr Margaret Chan, Director-General of the World Health Organization. "The credit goes to the Guinean Government, the people living in the communities and our partners in this project. An effective vaccine will be another very important tool for both current and future Ebola outbreaks." via WHO news Read More Here..
Lake forest health and fitness http://ift.tt/1KFVhKC
No comments:
Post a Comment